{"id":92039,"date":"2025-03-24T08:57:05","date_gmt":"2025-03-24T08:57:05","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/mrvi-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/"},"modified":"2025-03-24T08:57:05","modified_gmt":"2025-03-24T08:57:05","slug":"mrvi-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/mrvi-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","title":{"rendered":"MRVI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"},"content":{"rendered":"
\n

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP<\/strong><\/a> announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the \u201cClass Period\u201d), have until Monday, May 5, 2025 to seek appointment as lead plaintiff of the Maravai <\/em>class action lawsuit. Captioned Nelson v. Maravai LifeSciences Holdings, Inc.<\/em>, No. 25-cv-00499 (S.D. Cal.), the Maravai <\/em>class action lawsuit charges Maravai and certain of Maravai\u2019s top executives with violations of the Securities Exchange Act of 1934.<\/p>\n

If you suffered substantial losses and wish to serve as lead plaintiff of the <\/strong>Maravai <\/em><\/strong>class action lawsuit, please provide your information here:<\/strong><\/p>\n

https:\/\/www.rgrdlaw.com\/cases-maravai-lifesciences-holdings-inc-class-action-lawsuit-mrvi.html<\/strong><\/a><\/p>\n

You can also contact attorneys <\/strong>J.C. Sanchez<\/strong><\/a> or <\/strong>Jennifer N. Caringal<\/strong><\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at <\/strong>info@rgrdlaw.com<\/strong><\/a>.<\/strong><\/p>\n

CASE ALLEGATIONS<\/strong>: Maravai is a provider of biologics to support clinical research.<\/p>\n

The Maravai <\/em>class action lawsuit alleges that defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (i) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (ii) as a result, Maravai inaccurately recognized revenue on certain transactions during fiscal 2024; and (iii) Maravai\u2019s goodwill was overstated.<\/p>\n

The Maravai<\/em> class action lawsuit further alleges that on February 25, 2025, Maravai revealed that it was postponing its fiscal 2024 earnings release and would delay filing its annual report, noting that Maravai required additional time to complete its year-end financial close for reasons related primarily to \u201cits assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC,\u201d \u201can error identified during the close process with respect to revenue recognition associated with a single shipment identified in year-end audit procedures that resulted in approximately $3.9 million in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer,\u201d and \u201cthe effectiveness of its disclosure controls and procedures and internal controls over financial reporting as of December 31, 2024, and any remediation, including with respect to remediation of a material weakness in its internal controls over revenue recognition identified by management.\u201d On this news, the price of Maravai stock fell nearly 22%, according to the complaint.<\/p>\n

THE LEAD PLAINTIFF PROCESS<\/strong>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Maravai securities during the Class Period to seek appointment as lead plaintiff in the Maravai <\/em>class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Maravai <\/em>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Maravai <\/em>class action lawsuit. An investor\u2019s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Maravai <\/em>class action lawsuit.<\/p>\n

ABOUT ROBBINS GELLER<\/strong>: Robbins Geller Rudman & Dowd LLP is one of the world\u2019s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases \u2013 over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs\u2019 firms in the world and the Firm\u2019s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever \u2013 $7.2 billion \u2013 in In re Enron Corp. Sec. Litig.<\/em> Please visit the following page for more information:<\/p>\n

https:\/\/www.rgrdlaw.com\/services-litigation-securities-fraud.html<\/strong><\/a><\/p>\n

Past results do not guarantee future outcomes.\u00a0
Services may be performed by attorneys in any of our offices.\u00a0<\/p>\n

Contact:
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Robbins Geller Rudman & Dowd LLP
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0J.C. Sanchez, Jennifer N. Caringal
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0655 W. Broadway, Suite 1900, San Diego, CA 92101
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0800-449-4900
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0info@rgrdlaw.com<\/strong><\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the \u201cClass Period\u201d), have until Monday, May 5, 2025 to seek appointment as lead plaintiff of the Maravai class […]<\/p>\n","protected":false},"author":2,"featured_media":92040,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/a2879a30-a9fa-457e-97f6-7e2cd2528b7b","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-92039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/92039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=92039"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/92039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/92040"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=92039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=92039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=92039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}